Global Autoimmune and Inflammatory Immunomodulator

Dublin, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020" report to their offering. The global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period. The report also includes a discussion of the key vendors operating in this market.

One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug. Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel the market growth in the future. According to the report, one of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie's Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY).

The strong growth of Humira is attributed to the increasing prescription volume across various therapy areas, including rheumatoid arthritis and IBD. Also, TNF-alpha inhibitors such as Cimzia are posting substantial revenues owing to the increased adoption rates. Cimzia, a treatment for rheumatoid arthritis and Crohn's disease and other autoimmune diseases, reported revenue of $1.2 billion, indicating a YoY growth of 36% (base currencies). Key vendors

• AbbVie
• Johnson & Johnson
• Amgen
• F. Hoffmann-La Roche
• Pfizer

Other prominent vendors

• AstraZeneca
• Avaxia Biologics
• Biogen Idec
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Eli Lilly
• Enlivex Therapeutics
• Gilead Sciences
• Immune Pharmaceuticals
• Merck
• Mitsubishi Tanabe Pharma
• Neovacs
• Prometheus Laboratories
• Sandoz
• Sanofi
• Swedish Orphan Biovitrum
• Takeda Pharmaceuticals
• UCB

Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Autoimmune and inflammatory diseases Part 06: Pipeline portfolio Part 07: Market landscape Part 08: Market segmentation by type of disease Part 09: Market segmentation by molecule type Part 10: Geographical segmentation Part 11: Market drivers Part 12: Impact of drivers Part 13: Market challenges Part 14: Impact of drivers and challenges Part 15: Market trends Part 16: Vendor landscape Part 17: Key vendor analysis Part 18: Appendix For more information about this report visit http://www.researchandmarkets.com/research/67...autoimmune

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Immunosuppressive Drugs